10/10/2006

Roche will pay up to $700 million to Calif.-based biotech Plexxikon to create a new early-stage cancer therapy based on the biotech's compound, which attracted a lot of attention. The drug selectively inhibits a genetic mutation, called B-RafV600E kinase, found in more than 70% of malignant melanomas and a large percentage of other cancers and tumor types.

Related Summaries